CHEN's Stock Picks

 

Chen's Companies Visited - Sorrento Therapeutics in New York City | November 2017

CEO Henry Ji discuss SRNE pipeline at their new office in NYC
CEO Henry Ji discussed SRNE pipeline at their new office in NYC.
Compare SRNE new product(right) with the market leader Endo(left). SRNE is much lighter, stickier and it only use 3% of the drug to reach same results.
Comparing SRNE new product(right) with the market leader Endo(left). SRNE is much lighter, stickier and it only uses 3% of the drug to reach the same results.
Scilex (72% owned by SRNE) CEO Anthony Mack demonstrated how easy to stick the new generation product on joint, which Endo can't.
Scilex (72% owned by SRNE) CEO Anthony Mack demonstrated how easy it is to stick the new generation product on joint. Endo cannot do that.
You can still move your joint afterwards, which Endo can't
You can still move your joint afterwards. Endo cannot do that.
Easy to peel off afterwards. There is a huge cost advantage, only 50c 1/3 of Endo. SRNE believes once it is approved in February 2018, it can take over the whole 700 million market.
Easy to peel off afterwards. There is a huge cost advantage, only 50c, 1/3 of Endo. SRNE believes once it is approved in February 2018, it can take over the whole 700 million dollars market.
 




|   Home   |   Subscribe   |   Interview   |   Company Visited   |   Outlook   |   Strategy   |  Miningstocks.com   |